侵袭性霉菌病治疗的新型抗真菌药物
本文综述了近5年针对侵袭性霉菌感染的新型抗真菌药物研究数据,涵盖rezafungin、ibrexafungerp、oteseconazole等已获批药物及fosmanogepix、opelconazole、olorofim等在研药物。fosmanogepix、olorofim和encochleated amphotericin B的临床数据在疗效和安全性方面具有前景。
要点
- WHO真菌优先病原体清单推动抗真菌药物研发。
- rezafungin、ibrexafungerp、oteseconazole已获FDA批准。
- fosmanogepix、olorofim和encochleated amphotericin B临床数据前景良好。
核心结论
- fosmanogepix、olorofim和encochleated amphotericin B的临床数据在治疗侵袭性霉菌感染的疗效和安全性方面均令人鼓舞。
- 这些新药为难治性感染提供了替代选择,并有望提供更好的疗效和安全性结局。
研究设计与样本
- 综述类文章,通过PubMed检索近5年发表的临床前和临床试验数据。
- 检索词包括Aspergillus fumigatus、Fusarium、Mucorales、Eumycetoma、Scedosporium、Lomentospora及多种抗真菌药物名称。
主要发现
- 三种新抗真菌药rezafungin、ibrexafungerp和oteseconazole近期获美国FDA批准,是抗真菌治疗领域的重大进展。
- 本文讨论了rezafungin、ibrexafungerp和oteseconazole作为抗霉菌药物的批准情况、当前适应症和研究进展。
- 文章还纳入了fosmanogepix、opelconazole、olorofim以及改良制剂和管线中药物的信息。
局限性
- 新型抗真菌药物的开发具有挑战性,原因包括靶点有限、耐药性出现和不良毒性特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Invasive fungal infections are emerging as a critical threat to healthcare, yet the disparity in development and approval of new antifungal agents has only recently been addressed. In 2022, the WHO published the first global priority list of fungal pathogens (Fungal Priority Pathogens List) in order to promote public health awareness, encourage research and development, and propose actions and strategies for stakeholders to target in combatting the rise of fungal infections. OBJECTIVES: This review provides a summary of recent data of recently approved and/or investigational antifungals targeted at invasive mould infections, collating updated information on clinical findings of antifungal agents with potential use or activity against moulds listed on the WHO Fungal Priority Pathogens List. SOURCES: A PubMed literature search 'Aspergillus fumigatus', 'Fusarium', 'Mucorales', 'Eumycetoma', 'Scedosporium', and 'Lomentospora' with names of antifungal agents 'rezafungin', 'ibrexafungerp', 'oteseconazole', 'opelconazole', 'fosmanogepix', 'olorofim', 'BAL2062', 'mandimycin', 'ATI-2307', 'MAT2203', 'TFF voriconazole', and 'miltefosine' was conducted. CONTENT: Preclinical and clinical trial data published within the last 5 years are discussed. The recent approvals of three new antifungals by the US Food and Drug Administration are a significant accomplishment in the advancement of antifungal therapies. Approvals, current indications, and investigations for rezafungin, ibrexafungerp, and oteseconazole as antimould agents are discussed. Additionally, information on fosmanogepix, opelconazole, and olorofim, as well as reformulated agents and those in the pipeline, is included. Clinical data, where available, were the primary focus of the article. IMPLICATIONS: Development of new antifungal agents is challenging because of limited target sites, emergence of resistance, and adverse toxicity profiles. However, clinical data from fosmanogepix, olorofim, and encochleated amphotericin B are promising in both clinical efficacy and safety for the treatment of invasive mould infections. These new agents offer alternative options for difficult-to-treat infections, while providing promising efficacy and improved safety outcomes.
引用
- Vuong NN, McClung DR, Aitken SL, et al. New antifungals for the treatment of invasive mould disease. Clin Microbiol Infect. 2026. PMID: 41956397. doi:10.1016/j.cmi.2026.03.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。